Chronic Granulomatous Disease: A Lifetime of Injections or a Transplant Now
A six-year-old's liver abscess unmasks chronic granulomatous disease. The family isn't choosing between treatment and no treatment — they're choosing between decades of prophylaxis and interferon injections, or a transplant whose safety profile has changed enough in a decade to reopen a question that used to have an easy answer.
Desmond A. is six years old and has spent most of the last month in a hospital bed instead of at the day camp his older brother still gets to attend, after a fever that wouldn't break turned out to be a liver abscess growing Staphylococcus aureus — an organism his body should have been able to kill outright, not merely wall off into a collection large enough to need drainage. Before this admission he had been an otherwise healthy child by his parents' account, with only a history of one prior episode of lymphadenitis at age three that resolved with oral antibiotics and was never investigated further at the time. Genetic testing during this admission confirmed X-linked chronic granulomatous disease, a defect in the NADPH oxidase complex that normally lets neutrophils generate the burst of reactive oxygen needed to destroy certain bacteria and fungi after they've already been engulfed.
He has an older brother, unaffected, who is a confirmed full HLA match — a genuine asset most families facing this diagnosis don't have. The International Chronic Granulomatous Disease Cooperative Study Group's 1991 randomized, placebo-controlled trial of 128 patients found interferon-gamma, given three times weekly alongside standard prophylaxis, reduced serious infections from 9.7 to 3.6 per hundred patient-months — real, trial-level evidence for staying on medical management. But Güngör et al., 2014, Lancet, followed patients transplanted with reduced-toxicity conditioning across sixteen centers in ten countries and reported two-year overall survival above ninety percent — a result that has genuinely changed how early transplant gets discussed in this disease, no longer reserved as a last resort after medical management has already failed and organ damage has already accumulated. His liver imaging otherwise looks structurally normal once the abscess resolves, and he has no granulomatous colitis or lung nodules yet on the CT obtained during this admission — an early-stage disease picture that both specialists agree is exactly the window in which either path still has the best chance of working.
Medical management, transplant, or both starting today
He's about to start standard prophylaxis for the first time, and I'd add interferon-gamma from the start rather than wait for a second infection to justify it. The International CGD Cooperative Study Group's placebo-controlled trial cut serious infections from 9.7 to 3.6 per hundred patient-months with exactly that combination. That's a real, proven reduction with a well-tolerated drug, and he's already had one life-threatening infection this year.
I'm not arguing against starting interferon-gamma today — I'd do that regardless of what we decide about transplant. But I don't think medical management should be the default plan going forward. Güngör and colleagues followed patients transplanted with reduced-toxicity conditioning across sixteen centers and found two-year survival above ninety percent. He has a full-match sibling donor already identified. That combination didn't exist when watchful medical management became the standard first move in this disease.
A 63% relative reduction in serious infections is real, but it's a reduction, not elimination — he already had a life-threatening abscess on no prophylaxis at all. I don't think the interferon-gamma data answers what happens to his liver and lungs over the next decade of even reduced infection frequency.
Both of these can start moving today without either one waiting on the other. Start TMP-SMX, itraconazole, and interferon-gamma now — none of that delays or complicates a transplant referral, and it protects him during the months a full transplant workup takes regardless of the family's eventual decision. Send the sibling-donor transplant referral in parallel rather than sequentially, since a full-match donor and this trial-level survival data are exactly the circumstances in which waiting for a treatment failure no longer makes sense.
Prophylaxis and interferon-gamma started the same week, alongside a transplant referral sent to the same center that would eventually perform it, rather than waiting to see how he did on medical management first. The sibling donor workup proceeded over the following two months while he remained infection-free on the new regimen.
Agreed by all three once the parallel-track approach was proposed: nobody's underlying position needed to lose for the family to get both a real chance at durable medical stability and the shortest realistic path to a curative transplant, which the family ultimately chose to proceed with once the sibling donor workup cleared.